NCX 434 is a nitric oxide (NO)-donating new molecular entity (NME) and a potential preclinical candidate in diabetic macular edema (DME).
NicOx’s new preclinical study demonstrated that NCX 434 was effective in reducing several biochemical and functional aspects of retinal damage in a preclinical model of ischemia/reperfusion induced by the injection of ET-1.
Additionally, NCX 434 did not change IOP in this model, while triamcinolone acetonide, a reference steroid, resulted in an increase in IOP.
The previous preclinical results showed that NCX 434 enhanced oxygen saturation in various optic nerve head structures in contrast to a reference steroid were presented recently at the Ocular Diseases & Drug Discovery conference in Boston.